News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sunovion Pharmaceuticals Inc. Release: Once-Daily Aptiom® (Eslicarbazepine Acetate) For The Adjunctive Treatment Of Partial-Onset Seizures Now Available In U.S. Pharmacies



4/7/2014 10:15:05 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. (Sunovion) announced that Aptiom® (eslicarbazepine acetate), a once-daily antiepileptic drug (AED) indicated for use as adjunctive treatment of partial-onset seizures, is now available by prescription in pharmacies across the United States. APTIOM, a voltage-gated sodium channel blocker, is a new chemical entity approved by the U.S. Food and Drug Administration (FDA) on November 8, 2013, and is available in four tablet strengths (200 mg, 400 mg, 600 mg and 800 mg), which can be taken whole or crushed, with or without food. APTIOM is not classified as a controlled substance by the FDA.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES